Clinical trial · Interventional
NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer
A Prospective, Open, Randomized Controlled, Multicenter, Exploratory Clinical Study of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
NCT06669078CI-TRIAL-00082143NALIRIFOXnot yet recruitingPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the prospective, open, randomized controlled, multicenter, exploratory clinical study is to evaluate efficacy and safety of NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX for Conversion Therapy for Locally Advanced Pancreatic Cancer
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Locally Advanced Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Nal-lRl+Oxaliplain+5- FU | Drug | — | UNRESOLVED |
| Nal-lRl+Oxaliplain+5- FU +PD 1 | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- NALIRINOX combined with PD-1 synchronous sequential SBRT group
- description
- Nal-IRI+Oxaliplatin+5- FU +PD-1, these drugs are given on d1, d15, 28 days as one cycle, SBRT is performed during the third and fourth cycle.
- interventionNames
- Drug: Nal-lRl+Oxaliplain+5- FU +PD 1
- type
- EXPERIMENTAL
- label
- NALIRIFOX group
- description
- Nal-IRI+Oxaliplatin+5- FU, these drugs are given on d1, d15, 28 days as one cycle.
- interventionNames
- Drug: Nal-lRl+Oxaliplain+5- FU
Primary outcomes (1)
- measure
- 1 year OS rate
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: 1. Histologically or cytologically confi rmed pancreatic cancer; 2. ECOG performance no more than 1; 3. Radiographically assessed as locally advanced pancreatic cancer according ; 4. No previous anti-tumor therapy; 5. Able and willing to provide a written informed consent. Exclusion Criteria: 1. Prior anti-tumor therapy of any kind; 2. Known to be symptomatic central nervous system metastasis and/or cancerous meningitis. 3. Patients with autoimmune disease or immune deficiency who are treated with immuno-suppressive drugs; 4. Patients with bleeding tendency; 5. Pregnant or lactating women.
References
Publications (0)
Data not yet available
No reference posted for this study.